HK Stock Market Move | HENLIUS(02696) rises more than 3% against the market trend. Puhederju monoclonal antibody biosimilar drug POHERDY approved by the US FDA.

HENLIUS (02696) rose more than 3% against the market, as of press time, it rose 2.99%, to 67.2 Hong Kong dollars, with a turnover of 3.9331 million Hong Kong dollars. On the news front, HENLIUS and Organon jointly announced that the license application for the production of Pertuzumab injection solution POHERDY bioproduct has been approved by the US Food and Drug Administration (FDA) and can be used interchangeably with the original product PERJETA, becoming the first and only PERJETA biosimilar in the United States, covering all approved indications in the United States. It is worth noting that on November 12, the CDE official website announced that HENLIUS PD-1 antibody drug Sulilumabab injection (H drug) is planned to be included in breakthrough therapy for use in combination with neoadjuvant/adjuvant chemotherapy for gastric cancer, marking the first time it is planned to receive this designation. It is reported that the H drug is the world's first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer.